

15 JUNE 2017

APPOINTMENT OF CHIEF MEDICAL ADVISOR

- International medical cannabis expert, Dr. Danial Schechter, has been appointed as AusCann's Chief Medical Advisor
- Dr. Schechter will provide key advice and oversight of AusCann's Medical Outreach Program, applying his many years of experience treating patients in Canada with cannabinoid medicines.

AusCann Group Holdings Ltd (ASX:AC8 or 'the Company') is delighted to announce the appointment of Dr Danial Schechter as its Chief Medical Advisor. Doctor training and awareness forms a key part of the Company's strategy to educate the medical community on the potential benefits of cannabinoids as therapeutic agents to treat certain conditions, such as chronic pain.

Dr. Schechter has comprehensive knowledge of medical cannabis in practical clinical use. He has worked extensively within the field having founded the largest referral only clinic in Canada that specialises in cannabinoid medicine. Dr. Schechter has trained dozens of physicians in this field and has lectured at over one hundred events, both nationally and internationally, to thousands of physicians, pharmacists and patients about all aspects of cannabinoids. He has built up a unique skill set that includes patient care, cannabinoid education and business development within the cannabis space

Canada has allowed the use of cannabinoid medicines since 2001. A clear access system for the prescription of cannabinoid medicines by Canadian physicians was established in March 2014. Health Canada had around 130,000 registered patients at the end of last year, a 32% increase from the previous quarter and a significant increase from the original 7,900 granted access in mid-2014. (Source: Health Canada).

Cannabinoid medicines were rescheduled as Schedule 8 substances in Australia in November last year. Australian physicians may now apply to the Therapeutic Goods Administration and their relevant State/Territory health department for approval to prescribe. AusCann is dedicated to educating medical practitioners and furthering the medical community's understanding of how cannabinoids are currently being used therapeutically in other jurisdictions so that they may make informed decisions in respect to prescribing AusCann medicines.

Elaine Darby, Managing Director, AusCann said: "Australia is essentially where Canada was 3 years ago. At that point in time most Canadian doctors had not been provided with information that would enable them to make an informed decision on whether or how to prescribe cannabinoid medicines. We believe that Australian doctors will be greatly assisted by the knowledge that Canadian doctors have developed in prescribing these medicines."

Dr Danial Schechter said: "Australian physicians have not been taught about the endocannabinoid system in medical school or post graduate training. There is no formal curriculum to support a doctor who wants to learn about the endocannabinoid system and the therapeutic benefits of cannabinoid medicines. Because of this, a potentially valuable medication is not going to be prescribed to a large portion of the population who could significantly benefit from this. In order to rectify this situation, to allow patients access to cannabinoid medicines, it is crucial to support medical education."

Dr. Schecter will be working closely with AusCann to rollout the Medical Outreach Program. The aim of this Program is to educate Australian physicians on the endocannabinoid system and current knowledge of cannabinoid therapeutics and will involve ongoing seminars, webinars and online accredited courses. In addition, the Program will provide ongoing mentoring support to practitioner's prescribing AusCann's cannabinoid medicines.

The Company has already hosted educational seminars in Sydney Brisbane and Perth, each with strong attendance from interested practitioners focused on pain management and palliative care.

AusCann is focused on the medical need for more effective control of chronic and neuropathic pain in Australia, a market that represents over 3 million Australians. Earlier this year, the US National Academies of Science Engineering Medicine confirmed that there is substantial and conclusive evidence for the use of cannabinoid medicines in the treatment of chronic pain symptoms.

AusCann's first medicines are bring imported from their partner and major shareholder Canopy Growth, the largest producer in North America. AusCann will move towards Australian grown and manufactured cannabinoid medicines with their commercial licence to cultivate in place and their partnership with Tasmanian Alkaloids, the largest global producer of opiate pain control medicine ingredients.

For more information please contact

AusCann

Elaine Darby
Managing Director
elaine.darby@auscann.com.au
+61 8 9561 8834

For Investment Enquires

Stewart Washer
Stewart.washer@auscann.com.au
+61 418 288 212

For Media Enquiries

Caroline Zielinski
Media & Capital Partners
Caroline.zielinski@mcpartners.com.au
+61 400 172 145

ABOUT AUSCANN GROUP

AusCann is an Australian based company that was incorporated in September 2014 with the aim of producing and providing high quality, economical and clinically validated cannabis medicines to patients. It is bringing together leading expertise and operations across all aspects of the medical cannabis value chain, beginning with cultivation and production, through to manufacture and distribution of products and has built a strong team of experts and partners with international connections. Partners includes TSX listed Canopy Growth Corporations the largest producer of medicinal cannabis in North America, DayaCann, the only licensed medicinal cannabis grower in Chile and Tasmanian Alkaloids, producer of ~40% of the world's opiates.